These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37890053)

  • 41. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.
    Chandra A; Valkimadi PE; Pagano G; Cousins O; Dervenoulas G; Politis M;
    Hum Brain Mapp; 2019 Dec; 40(18):5424-5442. PubMed ID: 31520513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Yoon SH; Kim HK; Lee JH; Chun JH; Sohn YH; Lee PH; Ryu YH; Cho H; Yoo HS; Lyoo CH
    Neurology; 2023 Nov; 101(21):e2162-e2171. PubMed ID: 37813585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of amyloid PET Imaging in a Memory Clinic.
    Pletnikova A; Okhravi HR; Jamil N; Kirby M; Lyketsos CG; Oh ES
    Alzheimer Dis Assoc Disord; 2023 Oct-Dec 01; 37(4):270-273. PubMed ID: 37561943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tau PET in Alzheimer disease and mild cognitive impairment.
    Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
    Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels.
    Rubinski A; Franzmeier N; Neitzel J; Ewers M;
    Alzheimers Res Ther; 2020 Oct; 12(1):133. PubMed ID: 33076977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
    Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management.
    Shimohama S; Tezuka T; Takahata K; Bun S; Tabuchi H; Seki M; Momota Y; Suzuki N; Morimoto A; Iwabuchi Y; Kubota M; Yamamoto Y; Sano Y; Shikimoto R; Funaki K; Mimura Y; Nishimoto Y; Ueda R; Jinzaki M; Nakahara J; Mimura M; Ito D
    Neurology; 2023 Jan; 100(3):e264-e274. PubMed ID: 36175151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactions to Amyloid PET Scan Results and Levels of Anxious and Depressive Symptoms: CARE IDEAS Study.
    Bélanger E; D'Silva J; Carroll MS; Van Houtven CH; Shepherd-Banigan M; Smith VA; Wetle TT
    Gerontologist; 2023 Jan; 63(1):71-81. PubMed ID: 35436334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.
    Rauchmann BS; Ghaseminejad F; Mekala S; Perneczky R;
    Radiology; 2020 Jul; 296(1):134-142. PubMed ID: 32368960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of a [
    Coomans EM; de Koning LA; Rikken RM; Verfaillie SCJ; Visser D; den Braber A; Tomassen J; van de Beek M; Collij LE; Lemstra AW; Windhorst AD; Barkhof F; Golla SSV; Visser PJ; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM; van de Giessen E
    Neurology; 2023 Nov; 101(19):e1850-e1862. PubMed ID: 37748892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.